Clinical performance of an IGF1 LC-MS/MS assay and associated normative dataset in routine endocrinology
Authors' conclusion
Our LC-MS/MS IGF1 assay integrated with its own population-based normative dataset demonstrated superior alignment with clinical assessment compared with LBA results. In our setting, this method provides a clinically reliable benchmark for IGF1 interpretation and may serve as a reference for IGF1 harmonization and broader adoption of the Lifelines normative dataset in routine endocrinology.
Study context
- Population
- Paired IGF-1 results in routine endocrinology, adult and pediatric groupspaired IGF-1 results
- Participants
- 2,057 participants
- Comparison
- In-house LC-MS/MS IGF-1 assay with method-matched Lifelines normative dataset vs IDS iSYS ligand-binding assays (LBA)
- Outcome
- Agreement and clinical validity of IGF-1 SDS
Methodological detailsmethod comparison, paired samples
- Method comparison
- Paired samples
Performance
As reported in the abstract
Proportional bias
−27%
LC-MS/MS vs IDS iSYS
Weighted Cohen's κ
0.39
Between LC-MS/MS and IDS iSYS · categorical agreement fair
Original publication
Clinical performance of an IGF1 LC-MS/MS assay and associated normative dataset in routine endocrinology. Eur J Endocrinol. Published 27 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →